| P/E (FY) | 4.4 | Sales (TTM) | $32.7M |
| Earnings (TTM) | -$85.1M | ROE | 19.90% |
| Net Margin | 35.68% | ROIC | 468.04% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Keros Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for disorders linked to dysfunctional signaling of the TGF-beta family of proteins in the United States. It is developing rinvatercept, a ligand trap inhibiting myostatin and activin A, in Phase 1 trials for Duchenne muscular dystrophy and ALS, and elritercept targeting TGF-beta pathways in Phase 3 trials for myelodysplastic syndromes and Phase 2 for myelofibrosis. The company has agreements with Hansoh and Takeda.
| Market Cap | $381.2M | Trading Days | 1359 |
| 52W High | 22.55 |
| 52W Low | 9.69 |
| % Off High | −55.34% |
| YTD | −50.54% | 1Y | −30.60% |
| 3Y | −76.01% | 5Y | −73.27% |
| Since incept. (ann.) | −29.07% |
Reportable 100%
| Ann. Volatility (1Y) | 49.30% | Ann. Volatility (3Y) | 68.29% |
| Sharpe (1Y) | −0.51 | Sharpe (3Y) | −0.17 |
| Max Drawdown (1Y) | −54.62% | Max Drawdown (3Y) | −86.45% |
| Beta (3Y, vs SPY) | 1.56 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CAPR | CAPRICOR THERAPEUTICS, INC. | $380.5M | — |
| EBS | Emergent BioSolutions Inc. | $377.2M | 7.9 |
| PRLD | Prelude Therapeutics Inc | $369.6M | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $366.7M | — |
| LRMR | Larimar Therapeutics, Inc. | $397.9M | — |
| NATR | NATURES SUNSHINE PRODUCTS INC | $364.7M | 19.6 |
| AVIR | Atea Pharmaceuticals, Inc. | $360.9M | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $403.9M | 12.5 |
| EVMN | Evommune, Inc. | $405.2M | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $405.7M | 13.1 |
| DMAC | DiaMedica Therapeutics Inc. | $357.8M |
| — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $406.4M | — |
